Aligos Therapeutics (ALGS) Other Working Capital Changes (2019 - 2026)

Aligos Therapeutics (ALGS) has reported Other Working Capital Changes for 8 consecutive years, with -$831000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Working Capital Changes rose 16.65% year-over-year to -$831000.0; the trailing twelve-month figure through Jun 2026 stood at -$3.3 million (down 12.57% YoY), and the FY2025 full-year result was -$3.1 million, down 16.12% from the prior year.
• Other Working Capital Changes held at -$831000.0 in Q2 2026 per ALGS's latest filing, from -$834000.0 in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $1.2 million in Q4 2023 and bottomed at -$3.6 million in Q1 2022.
• Historically, Other Working Capital Changes has averaged -$507833.3 across 5 years, with a median of -$261000.0 in 2024.
• The widest YoY moves for Other Working Capital Changes: up 4204.95% in 2022, down 1043.45% in 2022.
• Over 5 years, Other Working Capital Changes stood at -$2.1 million in 2022, then jumped by 30.54% to -$1.5 million in 2023, then jumped by 51.92% to -$714000.0 in 2024, then retreated by 14.43% to -$817000.0 in 2025, then declined by 1.71% to -$831000.0 in 2026.
• According to Business Quant data, Other Working Capital Changes over the past three periods registered -$831000.0, -$834000.0, and -$817000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.